Does plasma exchange for longevity help you live longer or age slower?
No trial of plasma exchange in healthy older adults has measured lifespan or age-related disease. Small studies, including a 42-person Aging Cell trial, reported shifts in epigenetic clocks, with the strongest results when IVIG was added. A younger clock reading is a surrogate marker, not proof of a longer or healthier life.
Nov 17, 2026Updated Nov 18, 20269 min read

No human study has shown that therapeutic plasma exchange (TPE) helps people live longer or develop fewer age-related diseases, because none has measured those outcomes. The trials in healthy older adults report changes in blood markers and epigenetic clocks, which are tests that estimate "biological age" from chemical tags on DNA. As of November 2026, these are laboratory signals worth following. They are not proof of a longer or healthier life.
Does plasma exchange slow aging or help you live longer?
There is no human evidence that TPE extends lifespan or prevents age-related disease. The trials in healthy older adults measured safety and biological-age markers, not survival or illness.
How TPE works
In TPE, a machine separates plasma, the liquid part of blood, from blood cells. It discards the plasma and returns the cells with a replacement fluid. In the aging studies, the treatment replaces a patient's plasma with saline and purified albumin. Some studies follow it with intravenous immunoglobulin (IVIG), an antibody preparation.
TPE is distinct from three other procedures:
- Plasma donation.
- Dialysis.
- INUSpheresis, which filters a patient's own plasma and returns it.
The largest controlled trial in healthy adults over 50 stated that its primary objectives were to assess long-term TPE safety and changes in biological clocks.
Evidence status in 2026
| Status | What belongs here | What it shows |
|---|---|---|
| Established | TPE for specific diseases, which the American Society for Apheresis grades indication by indication. One example is thrombotic thrombocytopenic purpura, listed in the FDA-recognized AABB Circular of Information as an indication for plasma, including in plasma exchange | Benefit for named diseases, not for aging |
| Emerging | The 2025 Aging Cell trial (42 people), the 2022 GeroScience pilot (8 treated), AMBAR in Alzheimer's | Changes in biomarkers and clocks, and one disease trial with mixed results |
| Unproven | Longer life, fewer age-related diseases, "detox", clock rejuvenation counted as a health gain, young-donor plasma for aging | Not measured, or not shown |
Why a younger clock reading is not proof
An epigenetic clock is a surrogate marker: a laboratory estimate rather than a measure of health. A younger reading after TPE shows that the treatment changed the test. No TPE study has shown that this change leads to fewer heart attacks, less dementia or a longer life.
TPE's own research record shows why benefit has to be tested directly. In a trial in post-COVID condition (PCC), fifty subjects with PCC were randomly assigned (1:1) to receive six sessions of either TPE or a sham plasma exchange. The authors found that TPE, while safe, did not lead to any discernible improvement. The idea of clearing harmful factors from plasma sounded plausible, but the measured benefit did not appear. The sham-controlled long COVID trial is covered in more detail separately.
What did the human trials of plasma exchange for aging find?
Two small studies reported that TPE shifted biological-age markers, and neither measured disease or lifespan. In both, the strongest results came with IVIG added, so they cannot be credited to plasma removal alone.
The 2025 Aging Cell trial
The trial enrolled 42 individuals. It assigned them to bi-weekly TPE with or without IVIG, monthly TPE, or placebo.
The authors report 15 epigenetic clocks showing rejuvenation compared to placebo. Biweekly TPE plus IVIG was the most effective arm. Fifteen is a count of tests that moved, not of outcomes that improved.
The authors describe long-term TPE as safe. They report only two adverse events requiring discontinuation and one related to IVIG.
Three design features limit how much weight the results can carry:
- Allocation: the paper says randomization was based on entry date. That is not assignment by chance, and people who enroll early can differ from those who enroll later.
- Blinding: the title calls the trial single-blinded, meaning only one side of the study was masked to treatment.
- Size: 42 people split across four groups leaves each arm small.
The paper discloses that D.K. (co-founder and CSO), E.V., and D.F. are members of Circulate Inc., and that D.F. co-founded Edifice Health. Kiprov and two co-authors list an affiliation with Global Apheresis Inc., Mill Valley, California. That clinic appears in the price table below. These disclosed affiliations do not invalidate the data, but they belong next to the results.
The 2022 GeroScience pilot
An earlier pilot, co-authored by Kiprov, treated eight people aged 77, 67, 72, 68, 60, 72, 46 and 52. In each session, one plasma volume was removed and replaced with 5% albumin, followed by 2 g of 10% IVIG.
There was no randomized control arm. Instead, samples from treated people were compared with samples from untreated young and old donors.
The authors acknowledge that their variability test has various possible shortcomings in both power and significance when dealing with small sample sizes. They also note that only larger sample size ultimately increases power.
Some changes were temporary. Complement proteins, part of the immune system, fell as plasma was diluted. They returned to the initial levels by the next round ~ 1 month later. A correction to the paper was later published.
Does plasma exchange help Alzheimer's disease?
AMBAR, a trial in people already diagnosed with Alzheimer's, reported slower decline on a daily-living measure, only a trend on cognition, and no change in mild disease. Its authors concluded that plasma exchange could slow cognitive and functional decline in AD, although further studies are warranted.
Design
The trial randomized 347 patients into three plasma exchange arms and placebo (sham). Treatment had two phases:
- Six weeks of weekly conventional exchange.
- Twelve months of monthly low-volume exchange, with different doses of albumin and IVIG as replacement.
Results
The paper reports 52% less decline on the ADCS-ADL daily-living scale (P = .03). On the ADAS-Cog cognitive scale, decline was 66% lower, but at P = .06 that counted only as a trend. There were no changes in mild-AD patients (MMSE 22-26).
Funding and relevance
Six authors were full-time employees of Grifols, and others received Grifols funding to run the study.
For a healthy 60-year-old, AMBAR's relevance is limited. It studied a diagnosed disease with a specific albumin and IVIG protocol, and it measured disease progression, not aging.
Is plasma exchange for longevity FDA-approved or guideline-backed?
No. FDA clearance covers the apheresis machines, not longevity as a use, and the American Society for Apheresis (ASFA) grades plasma exchange one disease or condition at a time.
What the FDA cleared
The Spectra Optia was cleared on 08/02/2007 as a "Separator, Automated, Blood Cell And Plasma, Therapeutic". Clearance means the FDA found it substantially equivalent to existing devices.
The AMICUS system was cleared on 03/22/2012 for use in therapeutic plasma exchange. A cleared machine says nothing about whether a particular advertised purpose works.
What the guideline covers
ASFA's current guideline has 93 fact sheets and 183 graded and categorized indications. A clinic should be able to tell you which listed indication, if any, applies to you.
What one clinic says
Next Health says plasma exchange, being FDA-approved for other conditions, is being used off-label. It also says no claims are made as to whether this therapy is going to cure or treat any particular disease. The FDA action on record here is device clearance, not approval of TPE for particular conditions.
The same page calls it "Therapeutic Plasma Exchange, the most advanced longevity treatment available". It says its evidence base is among the fastest-growing in modern medicine. A growing number of publications is not the same as demonstrated benefit.
What are the risks, and who is this not for?
TPE has known side effects. For a healthy person, each risk is weighed against a benefit that has not been shown.
Common and rare side effects
The American College of Rheumatology (ACR) says patients may feel cold, nauseated, or experience mild tingling. Fatigue afterward is common. Rarely, patients have low calcium, vomiting, low blood pressure, or muscle cramps.
Risks tied to your health and setup
- Anemia: in people with anemia, plasmapheresis can make them more anemic.
- Central line: the ACR notes that a central line carries a small risk of infection and bleeding.
- Medications: plasma exchange can remove some medications.
Who this is not for
TPE for aging is not for anyone expecting proven life extension, disease prevention or a "reset". If you have anemia or take regular medications, raise both with a physician who knows your history before any clinic visit.
What does plasma exchange for longevity cost, and what should you ask?
As of November 2026, listed prices run from about $3,500 for a single low-volume session to nearly $60,000 for an extended protocol.
| Clinic | Listed price | Unit |
|---|---|---|
| Apeiron Center | From USD 3,500 | Per low-volume (1 liter) session |
| MDLifespan | $5,995; advanced protocols $15,995 to $59,995 | Per protocol |
| Global Apheresis | USD 15,000 / 28,000 / 40,000 | 2, 4 or 6-session series |
MDLifespan calls TPE "a safe, minimally invasive protocol that cleanses your blood". It says TPE works by "removing toxins and inflammatory proteins from the bloodstream". Neither toxin removal nor "cleansing" was an endpoint in the aging trials above.
Northvane's cost guide compares plasma exchange prices across listed clinics.
Questions to ask a clinic
- Which ASFA-graded indication, if any, applies to me, or is this off-label?
- What replacement fluid will you use: albumin alone, or albumin plus IVIG? What does IVIG add in cost and risk?
- What outcome will you measure, when, and what would count as no effect?
- Who performs the procedure, what venous access do you use, and how do you handle a reaction?
- How will my medications be timed around sessions?
- Do your physicians have financial ties to the tests or companies involved?
For a fuller list, see these questions to ask before booking plasma exchange.
Common questions
Is plasma exchange the same as young blood infusions?
No. TPE removes your plasma and replaces it with albumin, while young-blood treatments infuse plasma from young donors. In February 2019 the FDA said there is no proven clinical benefit of the infusion of plasma from young donors for aging or memory loss. It also noted infectious, allergic, respiratory, and cardiovascular risks.
Will insurance pay for plasma exchange for longevity?
Expect to pay yourself. MDLifespan, which sells a longevity program, says health insurance companies have not yet seen wisdom in covering this program. Treat longevity TPE as an out-of-pocket expense unless your insurer confirms otherwise in writing. Ask the clinic to itemize what a quoted price includes, such as IVIG, laboratory tests and venous access.
How long does a session take, and how often are sessions given?
The American College of Rheumatology says each session lasts a few hours, and fatigue afterward is common. The Aging Cell trial tested bi-weekly or monthly TPE, and the GeroScience pilot spaced rounds about a month apart. Ask how many sessions a clinic proposes and how it will judge whether to continue.
Sources13 cited
- [1](The page didn't return a title. The article is at https://link.springer.com/article/10.1007/s11357-022-00645-w) · link.springer.com
- [2]primary objectives were to assess long-term TPE safety and changes in biological clocks · doi.org
- [3]grades indication by indication · doi.org
- [4]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
- [5]Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial - Nature Communications · doi.org
- [6]Correction to: Old plasma dilution reduces human biological age: a clinical study - PMC · ncbi.nlm.nih.gov
- [7]A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. · doi.org
- [8]510(k) Premarket Notification · accessdata.fda.gov
- [9]510(k) Premarket Notification · accessdata.fda.gov
- [10]Therapeutic Plasma Exchange (TPE) · Next Health · next-health.com
- [11]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
- [12]Therapeutic Plasma Exchange Cost | MDLifespan · mdlifespan.com
- [13]MDL Longevity PlasmaXchange | Redefine Vitality and Slow the Signs of Aging - MDLifespan · mdlifespan.com
For information, not medical advice. Suggest a correction · Editorial policy


